Outlook until 2024/25
Elekta’s strategy provides the framework for our pursuit of profitable growth in a sustainable way and are quantified in the financial outlook.
Despite the post-pandemic impact Elekta had a net sales growth rate of 4% in 2022/23 based on constant
exchange rates. In SEK, net sales growth was 16%
In 2022/23, Elekta’s adjusted EBIT margin1) decreased to 10.3 percent. This was explained by a lower gross
margin, mainly due to inflation and supply chain challenges, as well as higher selling and administration
expenses. A Cost-reduction Initiative was implemented during 2022/23.
Elekta’s goal is to provide shareholders with a favorable return and value growth. The policy is to distribute at least 50 percent of profit for the year in the form of dividend, repurchase of shares or comparable measures. A dividend decision is based on Elekta’s financial position, earnings trend, growth potential and investment requirements.
For 2022/23 the dividend is 2.40 SEK/share, which corresponds to 97% of the net income.
Strategic milestones - outcome 2022/23
Availability of care
At end of year 2022/23 more than 184 million people in underserved markets had gotten access to treatment via Elekta’s installed base of linacs (baseline 2019/20).
Elevation of care
Online adaptive treatments are driven by Elekta Unity as the MR-Linac can adapt the treatment plan in real time to changing tumor and surrounding tissue anatomy.
100 percent of Unity treatments are adapted, of which around 60 percent are adapt to shape and around 40 percent adapt to position. More than 50 percent of Unity treatments are stereotactic body radiotherapy
Participation of care
Through the Kaiku app, patients can interact with their clinicians, who get access to the patients and their symptom feedback and will react to the patients
well-being, if necessary. A positive experience for the patient and efficient problem
solving for the clinicians